CN1331468C - 一种用于治疗癌症的植物提取物 - Google Patents
一种用于治疗癌症的植物提取物 Download PDFInfo
- Publication number
- CN1331468C CN1331468C CNB031080626A CN03108062A CN1331468C CN 1331468 C CN1331468 C CN 1331468C CN B031080626 A CNB031080626 A CN B031080626A CN 03108062 A CN03108062 A CN 03108062A CN 1331468 C CN1331468 C CN 1331468C
- Authority
- CN
- China
- Prior art keywords
- swainsonine
- cell
- tumor
- growth
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 63
- 201000011510 cancer Diseases 0.000 title abstract description 20
- 229960005566 swainsonine Drugs 0.000 claims description 103
- 239000003814 drug Substances 0.000 claims description 12
- 238000001959 radiotherapy Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 abstract description 12
- 108010063738 Interleukins Proteins 0.000 abstract description 12
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 239000000419 plant extract Substances 0.000 abstract description 8
- 239000000284 extract Substances 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 5
- 229940121354 immunomodulator Drugs 0.000 abstract description 4
- 239000002955 immunomodulating agent Substances 0.000 abstract description 3
- 230000002584 immunomodulator Effects 0.000 abstract description 3
- HHNUTZFOMIAQMX-UHFFFAOYSA-N Sphaerosin Chemical compound COC1=C(O)C=CC(C2CC3=CC=C(O)C=C3OC2)=C1OC HHNUTZFOMIAQMX-UHFFFAOYSA-N 0.000 abstract 4
- 235000010730 Ulex europaeus Nutrition 0.000 abstract 1
- 240000003864 Ulex europaeus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 67
- 241000147945 Oxytropis kansuensis Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 238000011282 treatment Methods 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 23
- 230000012010 growth Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000011160 research Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000010190 G1 phase Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 9
- 210000000683 abdominal cavity Anatomy 0.000 description 9
- 201000005619 esophageal carcinoma Diseases 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 239000003651 drinking water Substances 0.000 description 8
- 235000020188 drinking water Nutrition 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000018199 S phase Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 6
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001529246 Platymiscium Species 0.000 description 4
- 208000006268 Sarcoma 180 Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000220100 Oxytropis ochrocephala Species 0.000 description 3
- 241000293006 Oxytropis sericea Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000217952 Sphaerophysa salsula Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- -1 dimethyl methyl sulfones Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000004332 phalangeal cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WXELLRXNGRTSJY-VARJHODCSA-N (1s,2r,8r,8ar)-4-oxido-1,2,3,5,6,7,8,8a-octahydroindolizin-4-ium-1,2,8-triol Chemical compound C1CC[C@@H](O)[C@@H]2[C@H](O)[C@H](O)C[N+]21[O-] WXELLRXNGRTSJY-VARJHODCSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 101000804765 Mus musculus Lymphotactin Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
- 208000001792 Sarcoma 37 Diseases 0.000 description 1
- 101150011375 Tab2 gene Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000009950 gastric cancer growth Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- DXTIKTAIYCJTII-UHFFFAOYSA-N guanidine acetate Chemical compound CC([O-])=O.NC([NH3+])=N DXTIKTAIYCJTII-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- LWYXLXAMDLNBFQ-UHFFFAOYSA-N iso-6-Carnavalin Natural products CC(O)CCCCCCCCCCC1CCC(O)C(C)N1 LWYXLXAMDLNBFQ-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
小鼠肿瘤 | 肿瘤名称 | 抑制效果 |
B16鼠黑色素瘤细胞 | 单层培养时用苦马豆素处理24~48h,完全抑制。 | |
B16-F10鼠黑色素瘤细胞 | 在苦马豆素(3μg/ml)中亚融合培养24h,转移抑制率大于80%。 | |
S180腹水瘤 | 给小鼠接种后注射苦马豆素30~100mg/kg.d,连续5d,完全抑制。 | |
小鼠B16-BL16 | 小鼠饮水加苦马豆素,(3μg/ml)抑制自发率达88%。 | |
小鼠M5076网状肉瘤 | 小鼠饮水加苦马豆素,(3μg/ml)转移抑制率95%。 | |
人类肿瘤 | HT29结肠癌 | 苦马豆素单用或结合γ-干扰素使用,能有效制备体内生长的人HT29结肠癌。 |
concentration(mg·L-1) | Case(n) | absorbency A | Cell survival rate(%) |
12.8 | 9 | 0.003±0.002b | 0.5 |
6.4 | 9 | 0.005±0.003b | 0.9 |
3.2 | 9 | 0.086±0.012b | 15.0 |
1.6 | 9 | 0.135±0.028b | 23.5 |
0.8 | 9 | 0.352±0.030b | 61.2 |
0.4 | 9 | 0.409±0.045b | 71.1 |
0.2 | 9 | 0.460±0.041b | 80.0 |
0.1 | 9 | 0.508±0.035 | 88.3 |
0.05 | 9 | 0.553±0.033 | 96.2 |
0.01 | 9 | 0.575±0.043 | 100 |
control | 9 | 0.578±0.040 | - |
group | dosemg·kg-1 | Body weight(g) | Weight ofspleen(g) | Weight oftumor(g) | Inhibitionrate(%) | |
before | after | |||||
NS | - | 23.2±1.5 | 25.7±1.5 | 0.23±0.04 | 1.75±0.55 | - |
5-Fu | 22.5 | 24.1±2.0 | 23.0±1.6 | 0.18±0.07 | 0.77±0.40b | 56.0 |
Large | 16 | 23.5±1.6 | 26.1±3.9 | 0.22±0.05 | 0.88±0.54b | 49.7 |
middle | 8 | 24.2±2.2 | 26.3±3.1 | 0.22±0.06 | 0.98±0.49b | 44.0 |
small | 4 | 23.0±1.9 | 25.5±1.8 | 0.21±0.05 | 1.21±0.53b | 30.9 |
group | dosemg·kg-1 | Body weight(g) | Weight ofspleen(g) | Weight oftumor(g) | Inhibitionrate(%) | |
before | After | |||||
NS | - | 20.8±2.1 | 23.1±1.7 | 0.24±0.10 | 1.56±0.42 | - |
5-Fu | 22.5 | 21.4±1.6 | 20.1±2.2 | 0.19±0.09 | 0.68±0.40b | 56.4 |
large | 16 | 20.7±1.7 | 22.9±2.1 | 0.22±0.07 | 0.79±0.45b | 49.4 |
middle | 8 | 21.3±2.1 | 23.2±1.8 | 0.22±0.08 | 0.90±0.38b | 42.3 |
small | 4 | 21.8±2.1 | 24.3±2.0 | 0.23±0.09 | 1.12±0.52b | 28.2 |
group | dose/mg·kg-1 | Body weight/g | Weightofspleen/g | Weightoftumor/g | Inhibitionrate/% | WBC/109·L-1 |
before After | ||||||
NS | - | 23.3 26.1±1.3 ±3.0 | 0.23±0.09 | 1.55±0.56 | - | 5.68±1.75 |
5-Fu | 22.5 | 22.4 18.5±2.1 ±2.7b | 0.11±0.07b | 0.70±0.44b | 54.8 | 3.22±0.66b |
Radiotherapyalone | - | 21.8 22.3±1.9 ±2.4a | 0.14±.06b | 0.99±0.48b | 36.1 | 3.57±0.54b |
Radiotherapyand SW | 4 | 21.4 24.5±2.0 ±3.1 | 0.18±0.05b | 0.55±0.42b | 64.5 | 6.39±1.34 |
苦马豆素浓度(Swainsonine’scentitrate)(μg/ml) | G1(%) | S(%) | G2(%) |
5050.5对照组(controlgroup) | 40.038.526.321.7 | 52.853.260.762.7 | 7.28.313.015.6 |
苦马豆素浓度(Swainsonine’scentitrate)(μg/ml) | G1(%) | S(%) | G2(%) |
502510对照组(controlgroup) | 68.868.564.149.7 | 26.025.928.738.0 | 5.25.57.212.3 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031080626A CN1331468C (zh) | 2003-05-21 | 2003-05-21 | 一种用于治疗癌症的植物提取物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031080626A CN1331468C (zh) | 2003-05-21 | 2003-05-21 | 一种用于治疗癌症的植物提取物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1486692A CN1486692A (zh) | 2004-04-07 |
CN1331468C true CN1331468C (zh) | 2007-08-15 |
Family
ID=34152317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031080626A Expired - Fee Related CN1331468C (zh) | 2003-05-21 | 2003-05-21 | 一种用于治疗癌症的植物提取物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1331468C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151386B (zh) * | 2013-11-12 | 2017-01-11 | 毕毅良 | 苦马豆素衍生物及其科研试剂的制备方法 |
CN105481921B (zh) * | 2015-12-29 | 2018-04-06 | 中国科学院西北高原生物研究所 | 基于平行分离模式制备色谱分离棘豆中化合物方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1396161A (zh) * | 2002-05-24 | 2003-02-12 | 杨凌大农生物技术有限公司 | 疯草中苦马豆素的提纯工艺 |
-
2003
- 2003-05-21 CN CNB031080626A patent/CN1331468C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1396161A (zh) * | 2002-05-24 | 2003-02-12 | 杨凌大农生物技术有限公司 | 疯草中苦马豆素的提纯工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN1486692A (zh) | 2004-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102836367B (zh) | 一种抗菌消炎止痒的中药组合物及其制备方法和应用 | |
CN101485463A (zh) | 一种具有多种保健功效的天然产品组方 | |
CN102488682A (zh) | 绿原酸的抗癌新用途 | |
CN100420448C (zh) | 一种增强免疫力的保健食品及其制备工艺 | |
CN103735825A (zh) | 综合调理中药组合物及其应用 | |
CN109320570A (zh) | 一种淫羊藿次苷ⅰ类化合物、衍生物、可药用盐及应用 | |
CN102579803B (zh) | 一种治疗化疗后白细胞减少症的药物及其制备方法 | |
CN100522184C (zh) | 具有抗肿瘤和抗毒活性的提取物 | |
CN1331468C (zh) | 一种用于治疗癌症的植物提取物 | |
CN111920869A (zh) | 协同化疗药物治疗荷瘤小鼠的中药组方、制备方法及用途 | |
CN102008563B (zh) | 一种抗癌中药及其配制方法 | |
CN104622864A (zh) | 绿原酸在制备预防和治疗原发性皮肤t细胞淋巴癌的药物中的用途 | |
CN109106716A (zh) | 芒柄花素与氟尿嘧啶的组合在制备抗肿瘤药物中的用途 | |
CN102406858A (zh) | 一种消毒抗菌剂 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN101229362B (zh) | 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途 | |
CN101181440B (zh) | 一种治疗血液病的中药组合物及其制备方法和用途 | |
GB2593380A (en) | Antrodia cinnamomea extract, method for preparing antrodia cinnamomea composition, and pharmaceutical composition | |
CN100586443C (zh) | 一种红花桑寄生提取物的应用 | |
CN100358535C (zh) | 一种分枝杆菌多糖复合物及其制备方法 | |
CN103623143B (zh) | 一种藏药仁青常觉及其制剂在制备治疗白血病药物中的应用 | |
CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN107441076A (zh) | 一种治疗癌症的联合用药物 | |
CN101856393B (zh) | 一种复方益肝灵组合物在肿瘤化疗辅助治疗方面的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GE PENGBIN Free format text: FORMER OWNER: YANGLING DANONG BIOLOGY TECHNOLOGY CO., LTD. Effective date: 20080222 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080222 Address after: Business building Weiyi Shaanxi province Yangling demonstration zone Patentee after: Ge Pengbin Address before: Business building Weiyi Shaanxi province Yangling demonstration zone Patentee before: Danong Biotechnology Co., Ltd., Yangling |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070815 Termination date: 20110521 |